Aura Biosciences
Aura Biosciences specializes in developing targeted oncology treatments using a Virus-Like Particle platform, focusing on ocular and urologic cancers, with ongoing advanced trials and FDA Fast Track Designations.
Company Overview
Aura Biosciences develops a novel targeted oncology platform aimed at addressing multiple cancer indications, with a primary focus on ocular and urologic oncology. Utilizing a proprietary Virus-Like Particles (VLPs) platform, the company targets a wide array of solid tumors. Headquartered in Boston, MA, Aura Biosciences strives to create innovative solutions for conditions with high unmet medical needs.
Therapeutic Pipeline
Aura Biosciences offers a pipeline of therapeutic candidates targeting conditions with pressing medical needs such as ocular oncology and bladder cancer. Among their leading projects is the global Phase 3 CoMpass trial for Belzupacap Sarotalocan (Bel-sar), aimed at treating early-stage choroidal melanoma. Their endeavors are designed to tackle serious conditions using novel therapeutic approaches.
Ocular Oncology Focus
Aura Biosciences has a significant focus on ocular oncology, developing treatments for eye-related cancers. Their key project is Belzupacap Sarotalocan (Bel-sar), currently undergoing a global Phase 3 CoMpass trial for early-stage choroidal melanoma. This project represents their commitment to developing specialized treatments for ocular cancer patients.
Urologic Oncology Focus
In addition to ocular cancer, Aura Biosciences targets urologic cancers with its therapeutic candidates. The company has received Fast Track Designation by the FDA for developing treatments for non-muscle invasive bladder cancer (NMIBC). This designation highlights the urgent need and the potential effectiveness of their approach in treating urologic oncology conditions.
Innovative Technology Platform
Aura Biosciences utilizes a proprietary platform based on Virus-Like Particles (VLPs) to target and treat a broad range of solid tumors. This innovative technology enables the precise targeting of cancer cells, offering a new horizon in oncology treatment. The VLPs platform exemplifies Aura Biosciences' advanced scientific approach to oncology therapy development.